Date:11/2/2009

by financing activities 1,283,734 - --------- --- Effect of foreign currency translation - 16,745 --- ------ Net change in cash and cash equivalents (21,661,657) (490,814) Cash and cash equivalents, beginning of period 39,079,304 41,929,533 ---------- ---------- Cash and cash equivalents, end of period $17,417,647 $41,438,719 =========== =========== Supplemental disclosure of non-cash investing activities Intangible asset acquisition included in accounts payable $5,000,000 -

SOURCE Vanda Pharmaceuticals Inc.

'/>"/>

SOURCE Vanda Pharmaceuticals Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
2. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
3. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
4. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
5. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
6. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
7. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
8. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
9. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
10. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
11. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting